Dr. Reddy's Laboratories Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 3/6
Dr. Reddy's Laboratories has been growing earnings at an average annual rate of 26.4%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 12% per year. Dr. Reddy's Laboratories's return on equity is 18.9%, and it has net margins of 19.3%.
Anahtar bilgiler
26.4%
Kazanç büyüme oranı
26.4%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 17.5% |
| Gelir büyüme oranı | 12.0% |
| Özkaynak getirisi | 18.9% |
| Net Marj | 19.3% |
| Sonraki Kazanç Güncellemesi | 05 Nov 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Insufficient Growth At Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Hampers Share Price
Nov 01
Is Dr. Reddy's Laboratories (NSE:DRREDDY) Using Too Much Debt?
Oct 14If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity
Aug 19Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
Aug 01The Market Doesn't Like What It Sees From Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Earnings Yet
Jul 30Dr. Reddy's Laboratories (NSE:DRREDDY) Seems To Use Debt Rather Sparingly
Jul 12Dr. Reddy's Laboratories (NSE:DRREDDY) Will Pay A Dividend Of ₹40.00
Jun 23Additional Considerations Required While Assessing Dr. Reddy's Laboratories' (NSE:DRREDDY) Strong Earnings
Jun 20Dr. Reddy's Laboratories (NSE:DRREDDY) Is Paying Out A Dividend Of ₹40.00
May 26Dr. Reddy's Laboratories (NSE:DRREDDY) Will Pay A Dividend Of ₹40.00
May 10With EPS Growth And More, Dr. Reddy's Laboratories (NSE:DRREDDY) Makes An Interesting Case
May 06There Is A Reason Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Price Is Undemanding
Apr 18Earnings Beat: Dr. Reddy's Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Feb 02Should You Be Adding Dr. Reddy's Laboratories (NSE:DRREDDY) To Your Watchlist Today?
Jan 19Why Investors Shouldn't Be Surprised By Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Low P/E
Jan 01Dr. Reddy's Laboratories (NSE:DRREDDY) Has A Rock Solid Balance Sheet
Oct 21If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity
Oct 03Dr. Reddy's Laboratories (NSE:DRREDDY) Could Easily Take On More Debt
Jul 14Dr. Reddy's Laboratories (NSE:DRREDDY) Is Increasing Its Dividend To ₹40.00
Jun 24Dr. Reddy's Laboratories (NSE:DRREDDY) Is Paying Out A Larger Dividend Than Last Year
Jun 10Dr. Reddy's Laboratories (NSE:DRREDDY) Is Increasing Its Dividend To ₹40.00
May 27Dr. Reddy's Laboratories' (NSE:DRREDDY) Dividend Will Be Increased To ₹40.00
May 13Is Dr. Reddy's Laboratories (NSE:DRREDDY) Using Too Much Debt?
Apr 11If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity
Mar 06These 4 Measures Indicate That Dr. Reddy's Laboratories (NSE:DRREDDY) Is Using Debt Reasonably Well
Jan 10If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity
Dec 05Is Dr. Reddy's Laboratories (NSE:DRREDDY) A Risky Investment?
Sep 28Gelir ve Gider Dağılımı
Gelir ve Gider Dağılımı
Dr. Reddy's Laboratories nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 288,507 | 55,579 | 82,190 | 24,082 |
| 31 Mar 24 | 279,164 | 55,684 | 77,201 | 22,873 |
| 31 Dec 23 | 271,302 | 52,206 | 74,717 | 21,362 |
| 30 Sep 23 | 266,854 | 50,888 | 72,470 | 20,618 |
| 30 Jun 23 | 261,109 | 47,216 | 70,235 | 20,040 |
| 31 Mar 23 | 245,879 | 45,067 | 68,026 | 19,381 |
| 31 Dec 22 | 237,279 | 36,350 | 65,708 | 18,341 |
| 30 Sep 22 | 222,776 | 30,944 | 63,138 | 17,679 |
| 30 Jun 22 | 217,351 | 29,736 | 62,529 | 17,273 |
| 31 Mar 22 | 214,391 | 23,568 | 62,081 | 17,482 |
| 31 Dec 21 | 207,307 | 26,317 | 60,717 | 17,250 |
| 30 Sep 21 | 203,406 | 19,450 | 59,693 | 17,199 |
| 30 Jun 21 | 194,741 | 17,153 | 56,849 | 17,095 |
| 31 Mar 21 | 189,722 | 17,238 | 54,650 | 16,541 |
| 31 Dec 20 | 186,756 | 21,256 | 52,457 | 16,637 |
| 30 Sep 20 | 181,298 | 15,361 | 50,740 | 16,478 |
| 30 Jun 20 | 180,340 | 18,663 | 50,850 | 15,781 |
| 31 Mar 20 | 174,600 | 19,498 | 50,129 | 15,410 |
| 31 Dec 19 | 170,448 | 16,200 | 50,246 | 14,882 |
| 30 Sep 19 | 165,110 | 26,749 | 49,484 | 14,601 |
| 30 Jun 19 | 155,079 | 20,862 | 48,639 | 15,059 |
| 31 Mar 19 | 153,851 | 18,795 | 48,680 | 15,607 |
| 31 Dec 18 | 149,034 | 17,473 | 48,400 | 16,293 |
| 30 Sep 18 | 148,594 | 15,965 | 48,540 | 17,292 |
| 30 Jun 18 | 145,903 | 13,776 | 47,200 | 17,347 |
| 31 Mar 18 | 141,855 | 9,806 | 46,857 | 18,265 |
| 31 Dec 17 | 141,827 | 9,909 | 45,370 | 18,458 |
| 30 Sep 17 | 140,588 | 11,266 | 44,663 | 18,747 |
| 30 Jun 17 | 140,907 | 11,367 | 45,405 | 19,786 |
| 31 Mar 17 | 139,870 | 12,039 | 46,300 | 19,513 |
| 31 Dec 16 | 141,269 | 9,660 | 46,961 | 19,718 |
| 30 Sep 16 | 144,127 | 10,751 | 47,659 | 18,857 |
| 30 Jun 16 | 148,410 | 15,019 | 46,943 | 18,116 |
| 31 Mar 16 | 153,866 | 20,013 | 45,641 | 17,701 |
| 31 Dec 15 | 155,850 | 24,456 | 44,152 | 18,100 |
| 30 Sep 15 | 154,602 | 24,409 | 43,264 | 18,321 |
| 30 Jun 15 | 150,592 | 22,932 | 42,879 | 17,961 |
| 31 Mar 15 | 147,360 | 22,179 | 42,076 | 17,329 |
| 31 Dec 14 | 143,474 | 21,806 | 42,810 | 16,289 |
| 30 Sep 14 | 140,380 | 22,247 | 42,102 | 14,952 |
| 30 Jun 14 | 138,076 | 23,409 | 41,165 | 13,847 |
| 31 Mar 14 | 132,170 | 21,515 | 38,783 | 12,402 |
| 31 Dec 13 | 130,043 | 22,409 | 37,695 | 10,852 |
Kaliteli Kazançlar: DRREDDY has high quality earnings.
Büyüyen Kar Marjı: DRREDDY's current net profit margins (19.3%) are higher than last year (18.1%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: DRREDDY's earnings have grown significantly by 26.4% per year over the past 5 years.
Büyüme Hızlandırma: DRREDDY's earnings growth over the past year (17.7%) is below its 5-year average (26.4% per year).
Kazançlar vs. Sektör: DRREDDY earnings growth over the past year (17.7%) did not outperform the Pharmaceuticals industry 19.1%.
Özkaynak Getirisi
Yüksek ROE: DRREDDY's Return on Equity (18.9%) is considered low.